Carotid arteriosclerosis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:34:50 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Carotid arteriosclerosis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of [18F]AlF-NOTA-Octreotide for Carotid Artery Disease in Patients with Recent Stroke or TIA https://clinicaltrials.eu/trial/study-of-18falf-nota-octreotide-for-carotid-artery-disease-in-patients-with-recent-stroke-or-tia/ Wed, 29 Apr 2026 14:57:41 +0000 https://clinicaltrials.eu/trial/study-of-18falf-nota-octreotide-for-carotid-artery-disease-in-patients-with-recent-stroke-or-tia/ This clinical trial is focused on studying carotid artery disease, specifically a condition known as carotid artery atherosclerosis. This condition involves the buildup of fatty deposits in the carotid arteries, which can lead to serious health issues like strokes. The study will use a special imaging technique called PET/MRI to look at these arteries. The treatment being tested is a solution for injection called [18F]AlF-NOTA-Octreotide, also known by its code name [18F]-IMP-466. This solution is designed to help doctors see the arteries more clearly during the imaging process.

The purpose of the study is to explore how well [18F]AlF-NOTA-Octreotide works in identifying and measuring the severity of carotid artery disease in patients who have recently experienced a stroke or a mini-stroke, also known as a transient ischemic attack (TIA). Participants in the study will receive an injection of the solution, and then undergo a PET/MRI scan. This scan combines two types of imaging: Positron Emission Tomography (PET), which shows how tissues and organs are functioning, and Magnetic Resonance Imaging (MRI), which provides detailed images of the body’s structures.

The study will follow participants over a period of time to see if the imaging results can help predict future health events, such as another stroke or other vascular complications. The goal is to better understand how this imaging technique can be used to assess the risk of these events and improve patient care. Participants will be monitored for any changes in their condition, and the information gathered will help researchers learn more about the potential benefits of using [18F]AlF-NOTA-Octreotide in managing carotid artery disease.

]]> Study on Rivaroxaban for Stabilizing Carotid Artery Plaques in Patients with Stable Peripheral Artery Disease https://clinicaltrials.eu/trial/study-on-rivaroxaban-for-stabilizing-carotid-artery-plaques-in-patients-with-stable-peripheral-artery-disease/ Wed, 29 Apr 2026 14:22:38 +0000 https://clinicaltrials.eu/trial/study-on-rivaroxaban-for-stabilizing-carotid-artery-plaques-in-patients-with-stable-peripheral-artery-disease/ This clinical trial is focused on studying the effects of the medication Rivaroxaban on a condition known as atherosclerosis, which involves the buildup of fatty deposits in the arteries. Specifically, the study looks at patients with stable peripheral artery disease and asymptomatic atherosclerotic plaque or narrowing in the carotid artery. These patients do not show symptoms related to brain blood flow issues, such as stroke or temporary vision loss.

The purpose of the study is to observe how Rivaroxaban affects the structure of atherosclerotic plaques in the carotid artery over time. This will be evaluated using a special imaging technique called 3D contrast-enhanced ultrasound, which helps visualize the plaques. Participants in the study will receive either Rivaroxaban or a placebo for a period of one year. The study aims to determine if the plaques become more stable, as indicated by changes in their appearance on ultrasound images.

Throughout the study, researchers will monitor changes in the volume of the plaques and any blood clots within them. They will also track major health events such as heart attacks, strokes, and other serious cardiovascular issues. The study is designed to provide valuable insights into the potential benefits of Rivaroxaban for patients with atherosclerosis in the carotid artery.

]]>